HomeAI · summaries
Storia in 5 fonti
Upfront Ivonescimab Plus Chemo Bests PD-1 Inhibitor Combo in Advanced NSCLC
HARMONi-6 showed 34% drop in death risk, but trial had an all-Asian population, expert warned
Confronto fonti
5 prospettive sulla stessa storiaTimeline cronologica
- ·
medpagetoday.com
Drug Combo for Lung Cancer Beats Pembrolizumab in First-Line Trial
Antibody-drug conjugate plus pembrolizumab superior to pembrolizumab alone in PD-L1 expressors
- ·
biopharmadive.com
Akeso, Summit drug extends survival in closely watched lung cancer trial
Ivonescimab reduced the risk of death by one-third compared to chemotherapy in a China-based study that’s seen as an important barometer for a class of cancer immunotherapies…
